Search Results - "Ahmed, Ikhlaaq"

Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey by Ahmed, Ikhlaaq, Sutton, Alexander J, Riley, Richard D

“…Objective To examine the potential for publication bias, data availability bias, and reviewer selection bias in recently published meta-analyses that use…”
Get full text

Evidence for the use of spinal collars in stabilising spinal injuries in the pre-hospital setting in trauma patients: a systematic review by Hawkridge, Katherine, Ahmed, Ikhlaaq, Ahmed, Zubair

“…Purpose Spinal collars were introduced in 1967 into the management of spinal trauma care as it was thought that this technique of immobilisation would prevent…”
Get full text

A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis by Debray, Thomas P.A., Moons, Karel G.M., Ahmed, Ikhlaaq, Koffijberg, Hendrik, Riley, Richard David

“…The use of individual participant data (IPD) from multiple studies is an increasingly popular approach when developing a multivariable risk prediction model…”
Get full text

Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments) by Hasan, Zeeshaan‐Ul, Ahmed, Ikhlaaq, Matin, Rubeta N., Homer, Victoria, Lear, John T., Ismail, Ferina, Whitmarsh, Tristan, Green, Adele C., Thomson, Jason, Milligan, Alan, Hogan, Sarah, Van‐de‐Velde, Vanessa, Mitchell‐Worsford, Liza, Kentley, Jonathan, Gaunt, Claire, Jefferson‐Hulme, Yolande, Bowden, Sarah J., Gaunt, Piers, Wheatley, Keith, Proby, Charlotte M., Harwood, Catherine A.

“…Background The risk of cutaneous squamous cell carcinoma (cSCC) is significantly increased in organ transplant recipients (OTRs). Clearance of actinic…”
Get full text

Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial by Malladi, Ram, Ahmed, Ikhlaaq, McIlroy, Graham, Dignan, Fiona L., Protheroe, Rachel, Jackson, Aimee, Moss, Paul, Nunnick, Jane, Siddique, Shamyla, Bishop, Rebecca, Elhaneid, Mohamed, Hodgkinson, Andrea, Craddock, Charles

“…Chronic graft-versus-host disease (cGvHD) is a major cause of non-relapse morbidity and mortality following allogeneic stem cell transplant. Over half of…”
Get full text

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study by Sgroi, Dennis C, Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J, Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A, Rea, Daniel, Bartlett, John M S

“…Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive…”
Get full text

Developing and validating risk prediction models in an individual participant data meta-analysis by Ahmed, Ikhlaaq, Debray, Thomas P A, Moons, Karel G M, Riley, Richard D

“…Risk prediction models estimate the risk of developing future outcomes for individuals based on one or more underlying characteristics (predictors). We review…”
Get full text

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia by Quek, Lynn, Ferguson, Paul, Metzner, Marlen, Ahmed, Ikhlaaq, Kennedy, Alison, Garnett, Catherine, Jeffries, Sally, Walter, Claudia, Piechocki, Kim, Timbs, Adele, Danby, Robert, Raghavan, Manoj, Peniket, Andrew, Griffiths, Mike, Bacon, Andrew, Ward, Janice, Wheatley, Keith, Vyas, Paresh, Craddock, Charles

“…Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify…”
Get full text

Meta-analysis of test accuracy studies: an exploratory method for investigating the impact of missing thresholds by Riley, Richard D, Ahmed, Ikhlaaq, Ensor, Joie, Takwoingi, Yemisi, Kirkham, Amanda, Morris, R Katie, Noordzij, J Pieter, Deeks, Jonathan J

“…Primary studies examining the accuracy of a continuous test evaluate its sensitivity and specificity at one or more thresholds. Meta-analysts then usually…”
Get full text

A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance by Meads, Catherine, Ahmed, Ikhlaaq, Riley, Richard D.

“…A risk prediction model is a statistical tool for estimating the probability that a currently healthy individual with specific risk factors will develop a…”
Get full text

Response to Gultekin et al. regarding SECRAB trial toxicity by Fernando, Indrajit N., Lax, Sian, Ahmed, Ikhlaaq

Get full text

Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: A systematic review and meta-analysis by Jayaram, Sharan Chakkyath, Muzaffar, Sayed Jameel, Ahmed, Ikhlaaq, Dhanda, Jagtar, Paleri, Vinidh, Mehanna, Hisham

“…Background Treatment of recurrent oropharyngeal cancer is widely thought to have poor outcomes. Justification for treatment, especially in advanced cases, can…”
Get full text

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study by Bartlett, John M S, Sgroi, Dennis C, Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J, Brachtel, Elena F, Pirrie, Sarah J, Schnabel, Catherine A, Rea, Daniel W

“…The Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio predicts benefit from extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast…”
Get full text

Abstract P2-11-02: Breast Cancer Index predicts benefit from extended endocrine therapy in HR+ breast cancer by Bartlett, John, Sgori, Dennis, Treuner, Kai, Zhang, Yi, Piper, Tammy, Shalunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine, Rea, Daniel

“…Abstract Background: Optimizing the duration of adjuvant endocrine therapy in patients diagnosed with early stage hormone receptor-positive (HR+) breast cancer…”
Get full text

Abstract GS4-09: Correlative studies of the breast cancer index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: A trans-aTTom study by Sgroi, Dennis C, Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J, Brachtel, Elena F, Pirrie, Sarah, Schnabel, Catherine A, Rea, Daniel W, Bartlett, John MS

“…Abstract Background: Several biomarkers such as estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and Ki67 have been implicated in the…”
Get full text

Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial by Bartlett, John, Sgroi, Dennis, Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C., Ahmed, Ikhlaaq, Basnet, Kristen M, Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel William

“…Abstract only 505 Background: The aTTom study is a prospective phase III trial that randomized 6953 HR+ women to stop or continue tamoxifen (TAM) for 5 more…”
Get full text

HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial by Bartlett, John, Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C., Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena F., Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel William

“…Abstract only 522 Background: BCI is a validated gene expression-based assay that stratifies patients based on risk of overall (0-10y) and late (post-5y)…”
Get full text

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial by Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert, Churn, Mark, Spooner, David, Latief, Talaat N., Agrawal, Rajiv K., Brunt, Adrian M., Stevens, Andrea, Goodman, Andrew, Canney, Peter, Bishop, Jill, Ritchie, Diana, Dunn, Janet, Poole, Christopher J., Rea, Daniel W.

“…•SECRAB is the largest chemo-radiotherapy trial to date in early breast cancer.•SECRAB showed a positive therapeutic benefit of using adjuvant synchronous…”
Get full text

Summarising and validating test accuracy results across multiple studies for use in clinical practice by Riley, Richard D., Ahmed, Ikhlaaq, Debray, Thomas P. A., Willis, Brian H., Noordzij, J. Pieter, Higgins, Julian P.T., Deeks, Jonathan J.

“…Following a meta‐analysis of test accuracy studies, the translation of summary results into clinical practice is potentially problematic. The sensitivity,…”
Get full text

Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised double‐blind placebo‐controlled trial by Ewies, AAA, Ahmed, I, Al‐Azzawi, F, Pitkin, J, Gupta, P, Persic, M, Sahu, B, Elgobashy, A, Barraclough, L, Woodman, J, Babrah, J, Bowden, S, Stocken, D, Billingham, L, Sundar, S, Rea, D

“…Objective To assess whether folic acid supplementation ameliorates hot flushes. Design Double‐blind, placebo‐controlled randomised trial. Setting Nine…”
Get full text